As of 2025-05-24, the Fair Value of Adaptimmune Therapeutics PLC (ADAP) is -2.73 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.28 USD, the upside of Adaptimmune Therapeutics PLC is -1,074.72%.
With the market price of 0.28 USD and our fair value calculation, Adaptimmune Therapeutics PLC (ADAP) is not a good investment. Investing in ADAP stocks now will result in a potential loss of 1,074.72%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -130.09 | -158.09 | -165.46 | -113.87 | -70.81 | -127.67 |
| YoY growth | 5.16% | -21.52% | -4.66% | 31.18% | 37.81% | 9.59% |
| Market Cap (mil) | 68.79 |
| P/E | |
| Forward P/E |
| EPS | -0.28 |
| Avg earnings growth rate | 9.59% |
| TTM earnings | -69.89 |